Why I would buy Nearmap and these ASX mid cap growth shares

Nearmap Ltd (ASX:NEA) shares are one of three in the mid cap space that I would buy right now…

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

I think the mid cap space is a great place to look for buy and hold investment ideas.

This is because I believe there are a good number of shares that have the potential to grow strongly over the next decade, potentially generating outsized returns for shareholders.

Three mid cap shares that I would buy this month are listed below:

a woman

Bravura Solutions Ltd (ASX: BVS)

It certainly has been a busy year for this fast-growing provider of software solutions for the wealth management, life insurance, and funds administration industries. After failing in its takeover approach for GBST, the company has made two successful acquisitions. Bravura picked up Midwinter for $50 million and FinoComp for $25 million. Both businesses are expected to bolster its offering and open it up to new and lucrative markets. I expect this to complement the growth of its increasingly popular Sonata wealth management platform.

Nearmap Ltd (ASX: NEA)

One of my favourite mid cap shares is Nearmap. It is a leading aerial imagery technology and location data company which has operations in both the ANZ and North American markets. It has been experiencing very strong demand for its services in both markets over the last couple of years, leading to impressive growth in its key Annualised Contract Value (ACV) metric. Pleasingly, this solid demand shows no signs of slowing, leading to management recently guiding to further strong ACV growth in FY 2020.

Paradigm Biopharmaceuticals Ltd (ASX: PAR)

This biopharmaceutical company is certainly a higher risk option, but I believe the risk/reward on offer makes it worth considering. This is due to the massive market opportunity its ZILOSUL drug has. ZILOSUL is the brand name of its repurposing of Pentosan Polysulfate Sodium (PPS). Paradigm is focusing on repurposing PPS to treat osteoarthritis, which is a market with over 31 million sufferers in the United States alone. Trial results have been very positive, which has allowed Paradigm to strengthen its balance sheet greatly. At the last count the company had a cash balance of ~$75 million. I believe these funds should comfortably see Paradigm through to a commercial launch, if it gets that far.

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of Bravura Solutions Ltd. The Motley Fool Australia owns shares of and has recommended Nearmap Ltd. The Motley Fool Australia has recommended Bravura Solutions Ltd. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Growth Shares

A woman is excited as she reads the latest rumour on her phone.
Growth Shares

Here's why experts rate these ASX 200 growth shares as buys

Healthcare, retail, and lithium... here's why analysts rate these growth shares highly right now.

Read more »

A cool young man walking in a laneway holding a takeaway coffee in one hand and his phone in the other reacts with surprise as he reads the latest news on his mobile phone
Broker Notes

Morgans names the best ASX 200 growth shares to buy in March

These growth shares have been tipped for big things by a leading broker...

Read more »

a small child and a pug dog sit in a go cart wearing old fashioned drivers headress and goggles as the drive along a country road with the boy holding his arm in the air and shouting as if celebrating their performance behind the wheel.
Growth Shares

Top ASX growth shares to buy in March 2023

Could these growth stocks be set to hit the accelerator?

Read more »

A businessman hugs his computer and smiles.
Growth Shares

Buy and hold these ASX 200 shares: brokers

These could be great options for investors looking for buy and hold investments.

Read more »

A man sees some good news on his phone and gives a little cheer.
Growth Shares

Analysts say these exciting ASX growth shares are buys this month

These could be the growth shares to buy right now according to analysts.

Read more »

A boy is about to rocket from a copper-coloured field of hay into the sky.
Growth Shares

2 explosive ASX growth shares to buy this month: analysts

There are different levels of growth and these shares are in the clouds...

Read more »

A man sees some good news on his phone and gives a little cheer.
Growth Shares

2 ASX growth shares to buy: Goldman Sachs

Goldman Sachs believes these ASX shares are well-positioned for strong growth.

Read more »

A young man sits at his desk working on his laptop with a big smile on his face due to his ASX shares going up and in particular the Computershare share price
Growth Shares

These are the ASX 200 shares to buy in March: experts

Now could be the time to pounce on these ASX 200 shares.

Read more »